Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort studyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This cohort study examined the composition of the gut microbiome in patients with schizophrenia (SCZ), comparing samples taken during acute illness and during remission. Researchers used 16S rRNA MiSeq sequencing to characterize fecal microbial communities and identify differences relative to healthy controls. They then built a random forest model to test whether genus-level and OTU-level microbial features could serve as diagnostic biomarkers for SCZ status.
Who was studied?
The study included 29 patients with schizophrenia who each contributed two fecal samples, one from the acute onset period and one from the remission period, for a total of 58 patient samples. An additional 29 fecal samples were collected from a healthy control (HC) group, bringing the total to 87 fecal samples analyzed. The abstract does not report ages, sex distribution, geographic origin, or other demographic details.
What were the most important findings?
A random forest model using three optimal genus-level biomarkers distinguished acute SCZ patients from healthy controls with an AUC of 0.76 (95% CI 0.63 to 0.89). Eleven OTU-level biomarkers were identified separating remission-phase SCZ patients from controls, yielding an AUC of 0.7 (95% CI 0.56 to 0.84) as a disease status marker. Gut microbiota composition differed both between SCZ patients and healthy controls and between the acute and remission phases of illness within patients.
What are the greatest implications of this study?
The findings support the potential of gut microbiota profiling as a non-invasive diagnostic tool for schizophrenia. Because microbial signatures differed between acute and remission states, the gut microbiome may also offer clues for assessing disease prognosis and monitoring illness phase. The authors suggest these microbial features could help guide targeted, microbiome-informed intervention in schizophrenia care.